Apimeds Pharmaceuticals US, Inc., is a clinical-stage biopharmaceutical company. The Company is engaged in developing Apitox, an intradermally administered bee venom-based toxin. It is focused on developing Apitox as a potential osteoarthritis (OA) treatment for patients with knee pain who failed to respond adequately to conservative non- pharmacologic therapy and simple analgesics.
公司代碼APUS
公司Apimeds Pharmaceuticals US Inc
CEOMenon (Vin)
網址https://www.apimedsus.com/
常見問題
Apimeds Pharmaceuticals US Inc(APUS)的當前股價是多少?
Apimeds Pharmaceuticals US Inc(APUS)的當前股價是 1.540。
Apimeds Pharmaceuticals US Inc 的股票代碼是什麼?
Apimeds Pharmaceuticals US Inc的股票代碼是APUS。
Apimeds Pharmaceuticals US Inc股票的52週最高點是多少?
Apimeds Pharmaceuticals US Inc股票的52週最高點是4.000。
Apimeds Pharmaceuticals US Inc股票的52週最低點是多少?
Apimeds Pharmaceuticals US Inc股票的52週最低點是1.370。
Apimeds Pharmaceuticals US Inc的市值是多少?
Apimeds Pharmaceuticals US Inc的市值是19.37M。
Apimeds Pharmaceuticals US Inc的淨利潤是多少?
Apimeds Pharmaceuticals US Inc的淨利潤為-1.39M。
現在Apimeds Pharmaceuticals US Inc(APUS)的股票是買入、持有還是賣出?
根據分析師評級,Apimeds Pharmaceuticals US Inc(APUS)的總體評級為--,目標價格為--。
Apimeds Pharmaceuticals US Inc(APUS)股票的每股收益(EPS TTM)是多少
Apimeds Pharmaceuticals US Inc(APUS)股票的每股收益(EPS TTM)是-0.497。